UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
Form 6-K
Report of Foreign Private Issuer
Pursuant to Rule 13a-16 or 15d-16
under the Securities Exchange Act of 1934
For the month of February 2026
Commission file number: 001-42834
REGENTIS BIOMATERIALS LTD.
(Translation of registrant’s name into English)
60 Medinat Hayehudim Street, 4676652, Israel
(Address of principal executive offices)
Indicate by check mark whether the registrant
files or will file annual reports under cover of Form 20-F or Form 40-F.
Form 20-F ☒
Form 40-F ☐
CONTENTS
Attached hereto and incorporated
herein is the registrant’s press release issued on February 17, 2026, titled “Regentis Expands its European Clinical Site
Network to Support its Commercial and Clinical Programs.”
A copy of the press release
is furnished herewith as Exhibit 99.1 and incorporated herein by reference.
EXHIBIT INDEX
| Exhibit No. |
|
|
| 99.1 |
|
Press release titled: “Regentis Expands its European Clinical Site Network to Support its Commercial and Clinical Programs.” |
SIGNATURES
Pursuant to the requirements
of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto
duly authorized.
| |
Regentis Biomaterials Ltd. |
| |
|
| Date: February 17, 2026 |
By: |
/s/ Ehud Geller |
| |
Name: |
Ehud Geller |
| |
Title: |
Chairman and Chief Executive Officer |
Exhibit 99.1
Regentis Expands its European Clinical Site
Network to Support its Commercial and Clinical Programs
With CE Mark approval, GelrinC is slated for
commercial launch in Europe in 2026
New clinical sites to support engagement with
leading orthopedic surgeons and centers of excellence in key European markets, strengthening Regentis’ positioning for commercial
launch and broader clinical adoption
Herzliya, Israel – February 17, 2026—Regentis Biomaterials
Ltd. (“Regentis” or the “Company”), a regenerative medicine company focused on innovative tissue repair solutions,
today announced the expansion of its European clinical site network into new countries, strengthening its infrastructure to support both
ongoing clinical programs including its pivotal Phase III U.S. Food and Drug Administration study and the Company’s commercial strategy
in Europe where GelrinC® has already received CE Mark approval for knee cartilage repair.
Building on its established clinical presence in Northern and Central
Europe, Regentis is now expanding into additional European regions, including Italy and Eastern Europe. With GelrinC® already CE Marked,
the expanded network is expected to support deeper engagement with leading orthopedic surgeons and centers of excellence in key European
markets, strengthening the Company’s positioning for commercial launch and broader clinical adoption.
“The addition of these new sites in Europe is an important strategic
step into a high-potential region with a large patient population, strong orthopedic surgical expertise, and significant unmet need in
cartilage repair and joint preservation,” stated Dr. Ehud Geller, Executive Chairman of Regentis. “We believe this expanded
European clinical network enhances our ability to attract the right commercial partner for the launch of GelrinC® in Europe and to
efficiently execute on clinical adoption, while also supporting our ongoing clinical study programs.”
Participating Clinical Sites Include:
| ● | Humanitas in Milan, Italy
One of Italy’s leading academic hospital groups, widely recognized for high-volume orthopedic and sports medicine care, advanced
surgical capabilities, and strong clinical research infrastructure. |
| ● | Fondazione I.R.C.C.S. in Pavia, Italy
A highly regarded Italian research hospital and academic center known for clinical excellence, multidisciplinary expertise, and the ability
to support complex clinical programs with high-quality execution. |
| ● | University Regensburg in Regensburg, Germany
A leading academic medical center in Germany with strong orthopedic and sports medicine expertise, a robust clinical research environment,
and extensive experience in cartilage repair and joint preservation. |
| ● | Clinical Center of Vojvodina in Vojvodina, Serbia
One of the largest and most important regional medical centers in Serbia, serving a broad patient population and supporting access to
a major orthopedic surgery catchment area. The site brings both clinical scale and strategic presence in a growing Eastern European market. |
| ● | University of Ljubljana in Ljubljana, Slovenia
A leading national academic institution and referral center, with broad orthopedic clinical capabilities, experienced surgical teams,
and a strong foundation for clinical research execution. |
| ● | Timiş County in Timişoara, Rumania
A major regional medical center serving a large patient population, expanding Regentis’ reach in Eastern Europe and supporting access
to a broad orthopedic referral base. |
About GelrinC®
Regentis’ lead product, GelrinC®, is a cell-free, off-the-shelf
hydrogel synchronized erosion and resorbable implant for the treatment of painful injuries to focal articular knee cartilage. As an innovative
regenerative medical product, GelrinC® offers an unprecedented solution that gives surgeons and payers an off-the-shelf, ready to
use, simple to perform, reliable, and cost-effective procedure that provides patients with a single, 10-minute procedure, faster recovery,
sustained pain relief, and functional improvement for more than 4 years, based on clinical study results to date. No effective off-the-shelf,
ready to use treatment for focal knee cartilage defects is currently available on the market. GelrinC® has CE Mark approval in the
European Union and is now being evaluated in a pivotal U.S. Food and Drug Administration (FDA) study, which has completed over 50% enrollment.
About Regentis Biomaterials
Regentis Biomaterials Ltd is a regenerative medicine company dedicated
to developing innovative tissue repair solutions that restore health and enhance quality of life. With an initial focus on orthopedic
treatments, Regentis’ Gelrin platform technology, based on synchronized, degradable hydrogel implants, regenerates damaged or diseased
tissue including inflamed cartilage and bone. Regentis’ lead product GelrinC®, is a cell-free, off-the-shelf hydrogel that is
eroded and resorbed in the knee, allowing the surrounding cells to regenerate the cartilage in a controlled and synchronous process. GelrinC®
aims to address a market of approximately 470,000 cases for cartilage knee repair annually in the U.S. where no off-the-shelf treatment
is available.
Forward Looking Statements
This press release contains “forward-looking statements”
that are subject to substantial risks and uncertainties. All statements, other than statements of historical fact, contained in this press
release are forward-looking statements. Forward-looking statements contained in this press release may be identified by the use of words
such as “anticipate,” “believe,” “contemplate,” “could,” “estimate,” “expect,”
“intend,” “seek,” “may,” “might,” “plan,” “potential,” “predict,”
“project,” “target,” “aim,” “should,” “will” “would,” or the negative
of these words or other similar expressions, although not all forward-looking statements contain these words, and include beliefs regarding
Regentis’ advancement towards commercialization. Forward-looking statements are based on Regentis’ current expectations and
are subject to inherent uncertainties, risks and assumptions that are difficult to predict. Further, certain forward-looking statements
are based on assumptions as to future events that may not prove to be accurate. Factors that may affect future results and may cause these
forward-looking statements to be inaccurate include, without limitation: the ability of our clinical trials to demonstrate safety and
efficacy of GelrinC or any future product candidate, and other positive results; the timing and focus of our preclinical studies and clinical
trials, and the reporting of data from those studies and trials; the size of the market opportunity for of GelrinC or any future product
candidate, including our estimates of the number of patients who suffer from the diseases we are targeting; our ability to accurately
identify demand for product candidates; the success of competing therapies that are or may become available; the beneficial characteristics,
safety, efficacy and therapeutic effects of our product candidates; our ability to obtain FDA approval for of GelrinC or any future product
candidate and obtain and maintain regulatory approval; our ability to obtain market acceptance of of GelrinC or any future product candidate
from the medical community and third-party payors; our plans relating to the further development of GelrinC or any future product candidate,
including additional disease states or indications we may pursue; existing regulations and regulatory developments in the United States
and other jurisdictions; our plans and ability to obtain or protect intellectual property rights, including extensions of patent terms
where available and our ability to avoid infringing the intellectual property rights of others; the need to hire additional personnel
and our ability to attract and retain such personnel; our estimates regarding expenses, future revenue, capital requirements and needs
for additional financing; our dependence on third parties; our financial performance and our ability to repay our loans and debts; and
our ability to negotiate favorable terms in any collaboration, licensing or other arrangements into which we may enter and perform our
obligations under such collaborations. For a more detailed description of the risks and uncertainties affecting Regentis, reference is
made to the Company’s reports filed from time to time with the Securities and Exchange Commission (“SEC”), including,
but not limited to, the risks detailed in the section titled “Risk Factors” in the final prospectus related to the public
offering filed with the SEC. Forward-looking statements contained in this announcement are made as of this date, and Regentis undertakes
no duty to update such information except as required under applicable law.
Contact:
acarlquist@medicavp.com
